

**ALBUMIN DIAGNOSTIC TEST RESPONSE AND CLINICAL EVOLUTION IN PATIENTS SUSPECTED OF HEPATORENAL SYNDROME**

Jesiel Ballerini, Maria Angelica Pires Ferreira, Guilherme Becker Sander, Leila Beltrami Moreira

**Objectives.** Evaluating the relation between albumin diagnostic test response and clinical evolution in hospitalized patients suspected of hepatorenal syndrome. **Methods.** We reviewed clinical and laboratorial data of hospitalized patients between March and November 2011 with albumin prescription for HRS test. **Results.** 26 consecutive HRS albumin tests were included. Patients received albumin 1g/kg/day for two days. Complete response to HRS test was defined as serum creatinine lower than 1.5 mg/dL after 48 h and partial response as a serum creatinine reduction, but above 1.5mg/dL. Patients were followed for three months. The mean age was 60.3 years (range: 42-80y); the most frequent cause for cirrhosis was alcoholic hepatic disease. Sixteen patients were classified as Child C, 9 as child B, one as Child A. The mean basal serum creatinine was 2.43 mg/dL (SD 1.04). The mean serum creatinine 48 hours after therapeutic test with albumin was 2,3 mg/dl; 9 of 26 (34%) patients were considered complete responders to albumin, 4 partial responders and 13 non-responders. SBP was not predictive of response to albumin (4/9 and 6/17;  $P=0.5$ ). Fifteen patients died during hospitalization, being 11 nonresponders, 2 partial responders and 2 responders ( $P<0.01$ ). The hospital stay was 15.6 days for responders and 27.5 for non-responders. None was transplanted at the time of the study. **Conclusion.** High mortality was observed among patients submitted to test for HRS with albumin. Non-response to albumin was more frequent than response, and was associated to higher mortality. **Discussion/Implications.** Our data contests the validity of add terlipressin to non-candidate to transplant/non-responders to albumin, because it seems to be a marker of an irreversible end-stage hepatic disease.